Dr Matthew Gregory, Chief Executive Officer
Matthew is co-founder of Isomerase and has been its CEO since its formation. He is an experienced drug discovery professional skilled in programme management and intellectual property rights protection. He has extensive experience of drug discovery development and was previously Director of Intellectual Property and Project Management at Biotica Technology Ltd. At Biotica, he managed the intellectual property and collaborative research on internal projects from 2005-2013, with particular therapeutic focus in infectious diseases, inflammation and oncology. In doing so, he was also responsible for segregating internal programmes from collaborative research. Matthew joined Biotica in 2003, having been involved with the company since 1999 when he was at the University of Cambridge working on production of novel rapamycin analogues and genetic manipulation of the biosynthetic pathway in Professor Peter Leadlay’s group. Matthew has over 20 years of experience in actinomycete genetics, is an author or inventor on over 40 patents, patent applications or publications and holds a BSc in Biochemistry and Genetics and a PhD in Molecular Genetics from the University of Nottingham.
Dr Steven Moss, Chief Technology Officer
Steven is a co-founder of Isomerase and is highly practiced at applying the chemical biology to drug discovery. In particular, Steven is experienced in applying Isomerase's bioengineering platform and semi-synthesis to generate microbial natural products with characteristics more suited to use as pharmaceuticals than the parent, and taking these discoveries through into manufacturing. From 2009 until 2013, Steven was the Director of Natural Products Chemistry at Biotica Technology Ltd., where he was responsible for all internal fermentation and chemistry as well as the management and technology transfer associated with outsourced manufacture and chemistry. Steven joined Biotica in 2002 as a Research Scientist and worked on a number of different microbial natural product based programmes across multiple therapeutic areas. Prior to that, he spent two years as a Post-Doctoral Research Associate with Professor Heinz G. Floss (University of Washington, Seattle) studying the biosynthesis of ansamitocin. Steven holds a BSc and PhD in Chemistry from the University of Durham, where he studied under Professor David O'Hagan. He is an author or inventor on over 50 scientific papers and US/EU patents.
Karen Reddy, Financial Controller
Karen joined Isomerase in April 2018, as Financial Controller.
Karen brings 15 years of financial experience, across various industries, including the biotech, property and media industries.Prior to joining Isomerase Therapeutics Limited, Karen worked as Financial Controller at Mission Therapeutics Limited, a VC-backed biotech company. During her time at Mission she assisted in implementing numerous improved financial processes and controls as well as implementing a new finance system. Prior to this, Karen was Financial Controller at The Whitfield Group, a privately-owned property owning & letting business where she was responsible for all aspect of finance and also sat on the operational and management leadership team assisting to make strategic decisions. Prior to this, Karen spent 6 years at BSkyB Plc, where she held a number of Finance roles including 3 years within Group Finance, liaising closely with auditors as well as in-house tax, treasury and legal teams.
Karen trained and qualified as an ACA with KPMG and has a BA (Hons) Business degree.
Steven M Martin PhD, Chief Business Officer
Steve joined Isomerase in 2016 to support the next phase of commercialisation of the Company's proprietary technology platform. Steve was previously CEO of Zuvasyntha Ltd where he managed the growth and strategic refocusing of the company including securing major research collaborations with global industry partners, various rounds of seed investment and a merger with a US biotech company.
Prior to this Steve was R&D Director at TMO Renewables, where he was responsible for internal and external programs developing an industrial biotech platform for the production of renewable fuels and chemicals. Whilst at TMO, he helped the Company raise more than £40m in funding, and set up and participated in more than twenty grant-funded collaborations with UK and overseas universities.
Prior to TMO, Steve was Head of Fermentation at Cubist Pharmaceuticals and was responsible for the UK pilot plant and the fermentation activities at two manufacturing sites. Steve’s technical background is in microbial fermentation, process optimisation and scale-up. He has taken processes from concept to commercialisation and most notably was lead fermentation scientist for the process development and scale-up of the first-in-class lipopeptide antibiotic daptomycin (Cubicin™). He has more than 20 years’ industrial experience in the development of microbial processes for applications in the pharmaceutical and industrial biotechnology sectors and has authored many peer reviewed scientific papers, articles and patents. Steve is also founding Director of Inspire Biotech Ltd and a visiting lecturer and industrial fellow at the University of Bath.
Professor Barrie Wilkinson, Non-Exec Director
Barrie is a co-founder of Isomerase and a Project Leader in the Department of Molecular Microbiology at the prestigious John Innes Centre (http://www.jic.ac.uk). He was previously VP of Research at Biotica. Barrie is an innovative scientist with experience that spans the breadth of discovery and lead optimisation in natural products chemical biology, and spent several years working at GSKs medicines research centre in the UK. He was educated and trained at the universities of Leeds, Washington & Cambridge and is an author/inventor on 95 scientific papers and patents.
Mr Robert Booth, Non-Exec Director
Rob is a highly experienced director with a strong mix of financial, operational and strategic skills gained in the UK and internationally in blue-chip multinationals and SMEs in the Pharmaceutical, Life Science and Technology sectors. Raised over £40M, successfully IPO’d on the main London market and involved in numerous M&A transactions. Built multi-disciplined, multi-site teams and customer and partner relationships. He has managed professional advisors and institutional and commercial investors. He is currently the COO at Linaro. Previous posts include CFO at Biotica, CEO at Pronostics, CEO at Synomics, Group FD at Tadpole plc and Group FD at Pharmacia GB.